statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Larimar Therapeutics initiated with bullish view at Leerink

For the last three days, A.I.dvisor has detected that LRMR's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Larimar Therapeutics (LRMR, $7.45) Aroon Indicator entered a Downtrend on April 01, 2024.

This is a signal that LRMR's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Larimar Therapeutics (LRMR, $7.57) RSI Indicator left the oversold zone on March 28, 2024

Larimar Therapeutics (LRMR, $7.57) Aroon Indicator entered a Downtrend on March 28, 2024.

Larimar Therapeutics (LRMR, $7.26) Aroon Indicator entered a Downtrend on March 27, 2024.

Larimar Therapeutics (LRMR, $7.2) Aroon Indicator entered a Downtrend on March 26, 2024.

Larimar Therapeutics (LRMR, $7.58) Aroon Indicator entered a Downtrend on March 25, 2024.

Larimar Therapeutics (LRMR, $7.58) RSI Indicator left the oversold zone on March 25, 2024

Advances in Nomlabofusp Development and Strategic Financing Position Company for FutureRelated Stocks: LRMR...

Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results

Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observedInitiated discussions...

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Volume	42,337.00
52-Wk High	$13.68
52-Wk Low	$2.18

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.24	--	--	N/A
Q4'23	-$0.25	-$0.30	-20.84%	MISSED
Q3'23	-$0.22	-$0.21	6.02%	BEAT
Q2'23	-$0.19	-$0.19	2.55%	BEAT
Q1'23	-$0.25	-$0.15	39.57%	BEAT

LRMR Larimar Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals